Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis
MS Hughes, S Lentzsch - Therapeutics and Clinical Risk …, 2023 - Taylor & Francis
Introduction Systemic AL amyloidosis, a plasma cell dyscrasia, is characterized by the
production of misfolded immunoglobulin light chain. These misfolded proteins aggregate …
production of misfolded immunoglobulin light chain. These misfolded proteins aggregate …
Efficacy and safety of daratumumab in multiresistant immune‐mediated thrombotic thrombocytopenic purpura
J Weisinger, R Bouzid, D Ranta… - British Journal of …, 2024 - Wiley Online Library
The immunosuppressive treatment of immune‐mediated thrombotic thrombocytopenic
purpura (iTTP) in patients with intolerance or refractoriness to the B‐cell depleting …
purpura (iTTP) in patients with intolerance or refractoriness to the B‐cell depleting …
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
D De Novellis, D Derudas, D Vincelli… - European Journal of …, 2024 - Wiley Online Library
Isatuximab, a novel anti‐CD38 monoclonal antibody, is approved in combination with
carfilzomib and dexamethasone (Isa‐Kd) in relapsed/refractory multiple myeloma (RRMM) …
carfilzomib and dexamethasone (Isa‐Kd) in relapsed/refractory multiple myeloma (RRMM) …